0.04USD
2.51 MUSD
192.64 MUSD
54.51 M
About Vanda Pharmaceuticals Inc.
Sector
CEO
Mihael Hristos Polymeropoulos
Headquarters
Washington
Website
Employees (FY)
203
Founded
2002
ISIN
US9216591084
FIGI
BBG000HT5MG6
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of NighttiVNDA: Vanda Pharmaceuticals Inc.
2020-12-01 18:22:00
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
VNDA - rally until 19.8VNDA seems to be working on a small correction before going up to major resistance at 19.8m. Possible buy areas are indicated in green.
Vanda Pharmaceuticals Receives FDA Approval to Proceed with InveVNDA: Vanda Pharmaceuticals Inc.
2020-10-26 16:01:00
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
Vanda Pharmaceuticals! Earnings 40% Trade!!FA:
Earings release- the last earnings where the estimate was higher than 0.05 per share it led to the stock rallying by 40%- unless, the earings surprise is a negative one; we can expect a rally from Vanda Pharmaceuticals.
TA:
Currently been trading in a limited channel- lack of momentum could
VNDA ParabolicParabolic uptrend. Bullish W formation, upsides expected if the uptrend holds. MACD can be seen to be climbing into bullish territory.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VNDA is 5.16 USD — it has increased by 3.89% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vanda Pharmaceuticals Inc. stocks are traded under the ticker VNDA.
Vanda Pharmaceuticals Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
VNDA stock is 7.51% volatile and has beta coefficient of 0.42. Check out the list of the most volatile stocks — is Vanda Pharmaceuticals Inc. there?
Vanda Pharmaceuticals Inc. revenue for the last quarter amounts to 38.82 M USD despite the estimated figure of 44.50 M USD. In the next quarter revenue is expected to reach 37.00 M USD.
Yes, you can track Vanda Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
VNDA stock has risen by 20.93% compared to the previous week, the month change is a 36.96% rise, over the last year Vanda Pharmaceuticals Inc. has showed a 17.25% decrease.
VNDA net income for the last quarter is −2.40 M USD, while the quarter before that showed 137.00 K USD of net income which accounts for −1.85 K% change. Track more Vanda Pharmaceuticals Inc. financial stats to get the full picture.
Today Vanda Pharmaceuticals Inc. has the market capitalization of 285.96 M, it has increased by 15.35% over the last week.
No, VNDA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VNDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vanda Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 203.00 employees. See our rating of the largest employees — is Vanda Pharmaceuticals Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vanda Pharmaceuticals Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vanda Pharmaceuticals Inc. stock shows the sell signal. See more of Vanda Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vanda Pharmaceuticals Inc. EBITDA is −10.94 M USD, and current EBITDA margin is −5.68%. See more stats in Vanda Pharmaceuticals Inc. financial statements.